ICU sedation, delirium & recovery
Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial
Primary resultResult — go to the resultAdjusted relative risk 0.98 95% CI 0.73–1.31- terminated prematurely for futility
- Terminated prematurely for primary endpoint futility on DSMB advice
Authors' conclusion
Haloperidol does not reduce delirium in critically ill delirious adults.
Study context
- Population
- Critically ill adults with delirium (ICDSC ≥ 4 or positive CAM-ICU) in 8 mixed medical-surgical Dutch ICUs, February 2018 to January 2020
- Participants
- 132 adults
- Comparison
- IV haloperidol vs placebo
- Haloperidoln = 65
- Placebon = 67reference
- Primary endpoint
- ICU delirium- and coma-free days (DCFDs)
- Follow-up
- Within 14 days after randomization
Methodological detailsmulticentre, double-blind, placebo-controlled
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Adjusted relative risk
0.98
95% CI 0.73–1.31
P = 0.87
Haloperidol vs Placebo
adjusted RR 0.98 (95% CI 0.73–1.31); P = 0.87
Secondary outcomes
| Outcome | Estimate | P value | |
|---|---|---|---|
| Benzodiazepine use | adjusted OR 0.41 (95% CI 0.18–0.89) | P = 0.02 | |
| Use of open label haloperidol | OR 0.43 (95% CI 0.12–1.56) | ||
| Use of other antipsychotics | OR 0.63 (95% CI 0.29–1.32) | ||
| Self-extubation or invasive device removal | OR 0.70 (95% CI 0.22–2.18) | ||
| 0.10.31310Ratio (log scale) |
Safety
Adverse drug events
- Not different between groups
Original publication
Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial. Crit Care. Published 30 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →